Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > StupsNewcame dumber than a box of nails
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Biostocks01on May 21, 2021 1:34pm
122 Views
Post# 33248642

RE:RE:RE:RE:StupsNewcame dumber than a box of nails

RE:RE:RE:RE:StupsNewcame dumber than a box of nails
I follow the math :) I think there's some understanding of what the sale entails: the 70/30 split between LMNL & Kedrion is a one time event based on the potential sale of the PRV (the PRV has no relationship to the production/sale of Ryplazim, it's a voucher that can be sold on the secondary market to other pharma companies). As such, there will be no profit splitting for the ongoing production/sale of Ryplazim. If you have a source that states otherwise, please provide.

Bio
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities